The Role of MEK Inhibition in Pediatric Low-Grade Gliomas
Author Information
Author(s): Sheikh Shehryar R., Klesse Laura J., Mangum Ross, Bui Ashley, Siegel Benjamin I., Abdelbaki Mohamed S., Patel Neha J.
Primary Institution: National Pediatric Cancer Foundation (NPCF) Central Nervous System Task Force
Hypothesis
This mini-review explores the emerging role of MEK inhibitors in the management of pediatric low-grade gliomas (pLGGs).
Conclusion
MEK inhibitors show promise in transforming treatment paradigms for pediatric low-grade gliomas, potentially offering better outcomes than traditional chemotherapy.
Supporting Evidence
- MEK inhibitors can potentially interrupt the aberrant signaling cascade driving pLGG pathogenesis.
- Selumetinib showed a 36% sustained partial response in patients with BRAF mutations.
- Trametinib combined with dabrafenib resulted in a higher overall response rate compared to chemotherapy.
- Binimetinib demonstrated a 50% response rate in pLGG with BRAF mutations.
- Cobimetinib had a 9% partial response rate in pediatric patients with relapsed or refractory solid tumors.
- Mirdametinib achieved a 63% objective response in recurrent/progressive cases.
Takeaway
Doctors are looking at new medicines called MEK inhibitors to help kids with certain brain tumors called low-grade gliomas, which are usually hard to treat.
Methodology
This mini-review summarizes the molecular basis for MEK inhibition, reviews major MEK inhibitors, and discusses challenges in their use for pLGGs.
Potential Biases
Potential bias may arise from the authors' affiliations and the lack of financial support for the research.
Limitations
The review does not provide new clinical trial data but summarizes existing studies and their findings.
Participant Demographics
The review focuses on pediatric patients with low-grade gliomas, particularly those with BRAF mutations or neurofibromatosis type 1.
Statistical Information
P-Value
p<0.001
Statistical Significance
p<0.05
Digital Object Identifier (DOI)
Want to read the original?
Access the complete publication on the publisher's website